You are here: Home: Audio Program Guide: BCU 4 | 2008 Audio: BCU 4 | 2008
 
  Go to interview with Michael Gnant, MD
Go to interview with Charles L Vogel, MD
Go to interview with Hyman B Muss, MD
Go to interview with Matthew J Ellis, MB, BChir, PhD
Go to Fellows Rounds with Dr Vogel and Five Young
Mothers with Metastatic Breast Cancer
Go to Interview with Ms G
Go to Interview with Ms C
Go to Interview with Ms M
Go to Interview with Ms T
Go to Interview with Ms J
 


To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Gnant, MD Michael Gnant, MD
Professor of Surgery
Medical University of Vienna
Vienna, Austria
  
  Click here to download the entire interview  
Track 1 ABCSG-12: Adjuvant goserelin with tamoxifen or anastrozole with or without zoledronic acid in premenopausal women with hormone receptor-positive breast cancer
Track 2 ABCSG-12: Eligibility and patient characteristics
Track 3 ABCSG-12: Efficacy results of hormonal therapy
Track 4 Implications of ABCSG-12 for ongoing studies of adjuvant endocrine therapy
Track 5 Current endocrine therapy options for premenopausal patients
Track 6 Use of an LHRH agonist versus oophorectomy for premenopausal women

Track 7 Preliminary data from the ATLAS and aTTom trials evaluating five versus 10 years of adjuvant tamoxifen
Track 8 Extended therapy with an aromatase inhibitor (AI) for patients who become postmenopausal after five years of adjuvant tamoxifen
Track 9 ABCSG-12: Efficacy results of zoledronic acid
Track 10 “Seed and soil” hypothesis: Potential rationale for the effect of zoledronic acid on nonbone events
Track 11 Lack of bisphosphonate-associated osteonecrosis of the jaw in ABCSG-12
Track 12 Current clinical decisions regarding zoledronic acid
Track 13 Active US cooperative group trials evaluating adjuvant bisphosphonates
Track 14 Implications of ABCSG-12 for the completion of clinical trials
     
Vogel, MD Charles L Vogel, MD
Senior Research Advisor for Breast Cancer
Aptium Oncology
Lynn Regional Cancer Center
West Campus
Boca Raton Community Hospital
Scientific Advisor
Cancer Research Network Inc
Boca Raton, Florida
  
  Click here to download the entire interview  
Track 1 Case discussion: An 86-year-old woman with a 3.5-cm, Grade III, triple-negative, multiple node-positive (8+) breast tumor (from the practice of Dr William Adler)
Track 2 Adjuvant docetaxel/cyclophosphamide (TC) with pegfilgrastim in older patients
     
Muss, MD Hyman B Muss, MD
Professor of Medicine
University of Vermont and Vermont
Cancer Center
Hematology Oncology Unit
Burlington, Vermont
  
  Click here to download the entire interview  
Track 1 Case discussion of Dr Adler’s patient: Dr Muss’s response
Track 2 US Oncology 9735 trial comparing adjuvant TC to AC: Analysis of elderly patients
Track 3 Chemotherapy-associated AML and MDS in the elderly
Track 4 Quality-of-life benefits in preventing disease recurrence
Track 5 Breast cancer in the elderly: Increasing incidence, equivalent benefit from therapy and underaccrual to clinical trials
Track 6 CALGB-49907: Adjuvant capecitabine versus AC or CMF in elderly women with early breast cancer

Track 7 ICE trial: Adjuvant ibandronate with or without capecitabine in elderly patients
Track 8 Therapeutic algorithm for elderly patients with metastatic breast cancer (mBC)
Track 9 CALGB trial evaluating bevacizumab with either ixabepilone, weekly nab paclitaxel or weekly paclitaxel in mBC
Track 10 Ixabepilone for patients with metastatic disease
Track 11 ABCSG-12: Combining bisphosphonates with hormonal therapy
Track 12 Clinical use of zoledronic acid

Track 13 Adjuvant therapy for elderly patients with HER2-positive breast cancer
Track 14 Clinical algorithm for the treatment of patients with HER2-positive mBC
Track 15 Tolerability of capecitabine/lapatinib in the treatment of mBC

     
Elis, MD Matthew J Ellis, MB, BChir, PhD
Associate Professor of Medicine
Head, Section of Medical Oncology
Director, Breast Cancer Program
Washington University
School of Medicine
St Louis, Missouri		  
  Click here to download the entire interview  
Track 1 Development of an assay to identify biologic subtypes of breast cancer
Track 2 Development of a predictive model for benefit from endocrine therapy
Track 3 Reliability of ER testing
Track 4 ACOSOG-Z1031: A Phase III trial of neoadjuvant anastrozole, letrozole or exemestane in postmenopausal women with ER-positive breast cancer
Track 5 Perspective on ABCSG-12
Track 6 Clinical use of adjuvant bisphosphonates

Track 7 Vitamin D deficiency at breast cancer diagnosis and risk of distant recurrence and death
Track 8 Lapatinib alone or in combination with trastuzumab in heavily pretreated HER2-positive mBC progressing on trastuzumab
Track 9 Clinical experience with lapatinib
Track 10 Investigations in overcoming resistance to anti-HER2 therapy

Track 11 Long-term natural history of hormone receptor-positive breast cancer
Track 12 Preliminary ATLAS and aTTom results: Five versus 10 years of adjuvant tamoxifen
Track 13 Utilization of a risk-adapted approach in determining duration of adjuvant endocrine therapy
Track 14 BIG 1-98: Adjuvant letrozole versus tamoxifen versus sequential therapy with both in postmenopausal women with hormone receptor-positive breast cancer
Track 15 Clinical trial of physiological and high-dose estradiol in the treatment of hormone receptor-positive mBC

Track 16 AI-associated arthralgias and myalgias
Track 17 AVADO trial of docetaxel with or without bevacizumab as first-line therapy for mBC
     
  Fellows Rounds with Dr Vogel and Five Young Mothers with Metastatic Breast Cancer  
  Click here to download the entire discussion  
Track 1 Case discussion: Continued treatment of a patient who received paclitaxel/trastuzumab for mBC on the trastuzumab pivotal trial in 1995
Track 2 Side effects and tolerability of lapatinib
Track 3 A patient with a response to lapatinib in brain metastases
Track 4 Treatment algorithm for patients experiencing disease progression on trastuzumab
Track 5 Case discussion: A woman with HER2-negative, hormone receptor-positive breast cancer with 25/36 positive nodes with metastases diagnosed eight years after initial breast cancer diagnosis
Track 6 Long-term management of hormone receptor-positive early breast cancer

Track 7 Clinical use of capecitabine with or without bevacizumab for mBC
Track 8 Preferential use of nab paclitaxel for taxane-containing regimens
Track 9 Utility of tumor markers in patients with mBC
Track 10 Case discussion: A patient with significant weight gain during treatment with paclitaxel/bevacizumab for mBC
Track 11 Efficacy and tolerability of ixabepilone
Track 12 High-dose estradiol for patients with hormone receptor-positive, heavily pretreated mBC
Track 13 Case discussion: Response to single-agent capecitabine in a woman with liver, bone and brain metastases
Track 14 Clinical use of bevacizumab for patients with brain metastases
     
  Interview with Ms G

  
  Click here to download the entire interview  
Track 1 Perspective of a long-term survivor of mBC who was treated on the pivotal trastuzumab trial
Track 2 Supporting three young daughters while being treated for mBC
     
  Interview with Ms C

  
  Click here to download the entire interview  
Track 1 Breast cancer and motherhood
Track 2 Patient’s experience with disability from brain metastases
Track 3 Personal changes in outlook from living with cancer
     
  Interview with Ms M

  
  Click here to download the entire interview  
Track 1 Coping with breast cancer as a single mother
Track 2 Patient’s reaction to dramatic improvement of metastatic lesions with capecitabine and either placebo or bevacizumab on the RIBBON 1 trial
Track 3 Psychosocial and emotional impact of cancer treatment
Track 4 Incorporating cancer treatment into a busy daily life
     
  Interview with Ms T

  
  Click here to download the entire interview  
Track 1 Patient’s reaction to recurrence with mBC
Track 2 Patient’s experience during treatment with paclitaxel/bevacizumab
Track 3 Weight gain associated with corticosteroid premedication
Track 4 Switching from paclitaxel to nab paclitaxel without steroid premedication
Track 5 Impact of cancer on outlook in life
     
  Interview with Ms J

  
  Click here to download the entire interview  
Track 1 Tolerability of capecitabine
Track 2 Patient’s preference for oral chemotherapy
Track 3 Discussing mBC with a nine-year-old son